Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (vol 23, 136, 2023)

Basit Öğe Kaydı
dc.authoridPaksoy, Nail/0000-0003-4636-2595
dc.authoridOztosun, Bugra/0000-0003-2309-6781
dc.authoridTurker, Sema/0000-0001-9040-7266
dc.authoridHacıbekiroğlu, İlhan/0000-0002-0333-7405
dc.authoridKivrak Salim, Derya/0000-0003-4107-3460
dc.authoridErturk, Ismail/0000-0001-6835-0988
dc.authoridErul, Enes/0000-0002-2487-2087
dc.authorwosidPaksoy, Nail/HKF-3015-2023
dc.authorwosidmenekşe, serkan/HNP-3265-2023
dc.authorwosidOztosun, Bugra/IQV-6428-2023
dc.authorwosidSendur, Mehmet Ali Nahit/H-7555-2014
dc.authorwosidTurker, Sema/ABE-5926-2021
dc.authorwosidHacıbekiroğlu, İlhan/JCN-7264-2023
dc.authorwosidKivrak Salim, Derya/A-3920-2015
dc.contributor.authorKaracin, Cengiz
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorDemirci, Ayse
dc.contributor.authorKeskinkilic, Merve
dc.contributor.authorBaytemur, Naziyet Kose
dc.contributor.authorYilmaz, Funda
dc.contributor.authorSelvi, Oguzhan
dc.date.accessioned2024-06-12T11:22:25Z
dc.date.available2024-06-12T11:22:25Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstract[Abstract Not Available]en_US
dc.identifier.doi10.1186/s12885-023-10662-3
dc.identifier.issn1471-2407
dc.identifier.issue1en_US
dc.identifier.pmid36849943en_US
dc.identifier.scopus2-s2.0-85148970683en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1186/s12885-023-10662-3
dc.identifier.urihttps://hdl.handle.net/20.500.14551/25911
dc.identifier.volume23en_US
dc.identifier.wosWOS:000941147400001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBmcen_US
dc.relation.ispartofBmc Canceren_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject[No Keywords]en_US
dc.titleEfficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (vol 23, 136, 2023)en_US
dc.typeCorrectionen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu